title: Bartonella henselae infection during tocilizumab therapy.
authors.affiliation: Rheumatology, Brest teaching hospital, Brest, France.
authors.forename: Morgane
authors.initials: M
authors.lastname: Milin
authors.forename: Marie
authors.initials: M
authors.lastname: Acquitter
authors.forename: Rozenn
authors.initials: R
authors.lastname: Le Berre
authors.forename: Bruno
authors.initials: B
authors.lastname: Sassolas
authors.forename: Valérie
authors.initials: V
authors.lastname: Devauchelle-Pensec
authors.forename: Divi
authors.initials: D
authors.lastname: Cornec
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D018416:Bartonella henselae / Q000302:isolation & purification*; D002372:Cat-Scratch Disease / Q000175:diagnosis* / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000276:immunology / Q000382:microbiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab